ensifentrine

Ensifentrine (Ensifentrinum) 是首创的吸入式磷酸二酯酶 3 (PDE3) 和PDE4双重抑制剂，IC50分别为 0.4 nM 和 1479 nM。它具有支气管保护和抗炎作用，可用于研究慢性阻塞性肺疾病 (COPD) 。

(E Z)-Ensifentrine is a potent and selective PDE3 4 inhibitor. (E Z)-Ensifentrine acts as a long-acting inhibitor of the phosphodiesterase enzymes PDE-3 and PDE-4, producing both bronchodilator and antiinflammatory effects. It is being developed by Verona Pharma as a potential treatment for asthma and hay fever, and is currently in clinical trials.